Its phase IIb studies (NCT02706873, NCT02706951) demonstrated that among patients with moderate—to—severe RA who had an insufficient response to methotrexate (MTX) or anti—TNF therapy, the treatment groups achieved significantly higher ACR 20/50/70 response rates and more substantial improvements in DAS28—CRP scores compared to the placebo group, with a rapid onset of efficacy [404]. The gene discussed is CRP; the disease is rheumatoid arthritis.